ArticleAdvances in radiation oncology2026
High-Dose Carbon Ion Reirradiation for Recurrent Pelvic Sarcomas: A Retrospective Analysis of Oncologic Outcomes in a Referral Center.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate the safety and efficacy of high-dose carbon ion reirradiation (CIR) in patients with recurrent pelvic sarcomas. Methods and Materials: This retrospective study included 46 patients treated with high-dose CIR for locoregional recurrences of pelvic sarcomas between 2013 and 2023 at the National Center for Oncological Hadrontherapy, Pavia, Italy. Clinical outcomes, toxicity, and cumulative doses were analyzed. Results: The median prescribed total dose of CIR was 60 GyRBE (range, 45-73.6 GyRBE). The maximum cumulative equivalent dose in 2 Gy fractions to the target volume reached 284 Gy, with a median of 153 Gy. The median follow-up was 32.5 months. The 1-, 2-, and 3-year locoregional progression-free survival rates were 79.1%, 43.9%, and 25.1%, respectively, with a mean time to locoregional relapse of 18.9 months. The 1-, 2-, and 3-year overall survival rates were 100%, 93.9%, and 83.1%, respectively. At last follow-up, grade 3 neuropathy occurred in 6.5% of the patients, grade 3 anorectal dysfunction in 8.7%, and grade 3 skin toxicity in 6.5%. Conclusions: High-dose CIR is a feasible salvage strategy for recurrent pelvic sarcoma, offering promising outcomes and manageable toxicity in carefully selected patients. Prospective studies are warranted to refine dose-response models and validate long-term efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.